Clinicians can reassure myelofibrosis patients that the drop in hemoglobin often seen when starting ruxolitinib does not carry the same negative prognostic weight as anemia caused by the disease itself. This distinction is crucial for managing patient expectations and continuing effective therapy despite initial side effects.

A diagnosis of myelofibrosis without a JAK2, CALR, or MPL mutation should be treated as a red flag, not a final diagnosis. It warrants a deeper investigation for alternative causes, such as MDS/MPN overlap syndromes or secondary fibrosis from other conditions like autoimmune disease or hairy cell leukemia.

While beneficial for patients with prior weight loss, ruxolitinib can cause significant weight gain (20-30 pounds) in other myelofibrosis patients. This quality-of-life issue should be discussed proactively, as it can become a major concern, effectively trading one disease state for another.

Recent Phase 3 trials for novel myelofibrosis combinations (e.g., pelabrasib or selinexor with ruxolitinib) show a consistent pattern. They successfully reduce spleen volume but fail to demonstrate a statistically significant improvement in patient-reported symptom scores compared to ruxolitinib alone, questioning the link between these two endpoints.

For myelofibrosis patients with profound splenomegaly but only moderate thrombocytopenia (platelets 50k-100k), fedratinib may be the best frontline option. It is arguably the most potent JAK inhibitor for spleen reduction and is approved for use in patients with platelet counts as low as 50,000.

Concerns about bone marrow fibrosis with TPO receptor agonists have been resolved. The effect is a reversible increase in reticulin fibrosis, not the permanent collagen fibrosis seen in myelofibrosis. It resolves upon stopping the drug, so routine bone marrow biopsies for monitoring are unnecessary.

For myelofibrosis patients with both anemia and splenomegaly, a practical approach is to start with ruxolitinib for its superior symptom control. If the subsequent anemia is not well-tolerated, switching to momelotinib allows for a more informed, personalized decision based on the patient's experience with both agents.

Despite theoretical differences in potency or PARP1 specificity, all approved PARP inhibitors demonstrate comparable clinical toxicity profiles. Oncologists should counsel patients on a consistent class effect of myelosuppression, primarily grade 3 anemia requiring transfusion in about 25-33% of patients, regardless of the specific agent.

Newer TKI formulations ensure consistent drug absorption, correcting for under-dosing caused by food or other medications. While improving efficacy, this means more patients may experience the drug's known side effects. What seems like new toxicity could be the drug’s true profile, no longer masked by poor absorption.